Tag Archives: venture capital

Elucidating the Timeline to Capital

17 Apr

By Dennis Ford, CEO, LSN

LSN has written extensively on several facets of the capital-raising process, from the various new types of investors active in the space, to the technologies most actively being targeted by investors. However, we have not yet delved into the actual timeline required to raise money. This is the big question, as most emerging life sciences companies exist in a life-or-death situation. A misconceived notion of the required timeline to capital is the kiss of death for many; this article seeks to correctly define this critical period in the life of a company.

First things first: all of your collateral must be in order – this includes getting the business plan written along with the necessary investor presentation documents (powerpoint, executive summary, and website – yes, your website is an investor presentation tool!). This is a multifaceted process, which goes far beyond just explaining the science. Adroit entrepreneurs will know that as they write their plan, they are also creating a brand and a message that they are delivering to a marketplace of investors, and hopefully beyond. When writing the plan, keep in mind that the document you are creating is for distribution, and that it will be compared and contrasted with other companies that are going after the same capital as you are. If you take the time to present the data and create compelling facts & forecasts around your plan, then you have a leg up. Technology, market sizing and financial forecasting are all important elements, but don’t forget the most important one: your plan is your identity as a company! It can take anywhere from 6-8 weeks to develop and write a business plan, and then a considerable amount of ongoing time to hone and edit it as you move through the fundraising process.

The next step is compiling a global target list of investors that are likely candidates. You need to do your research and outline all of the likely candidate investors. This includes researching past investments in products like yours, groups targeting your specific disease area, and other relevant criteria that are major components of your company. This is why it is so important to have a cohesive understanding of who you are before seeking out investors. You will also want to research & target investors that have declared that they have a current or future mandate for investment in products that are like yours. This can be easy if you decide to buy an up-to-date database of investors, such as LSN’s. Alternatively, it can be incredibly time consuming if you decide to do this by vetting a list of likely investor fits through Internet research. Essentially, this is a process that can take a few clicks of your mouse with a good database, or over a month (or more) if researched manually. Here you must remember that accurate, current information on investors and investor contacts is paramount. Nothing creates thrashing like out-of-date data.

Then it is off to the outbound marketing campaign, and actually contacting investors – creating dialogue that turns into a relationship and, eventually, nets you an allocation. Contacting investors is a tedious, time consuming, and difficult process. It takes incredible tenacity to work your investor list and stay on the mission. Most of the time you spend will be doing referred outreach, cold calls, follow up, and more follow up. Most meetings involve multiple incantations and various follow-ups. This is because, realistically, it takes 2-6 weeks to regroup between follow-ups. What’s more, repeated meetings with various stakeholders can take months. All in all, the process of creating dialogue and developing a relationship takes a serious commitment of time and effort.

This is why it is important to know and understand the cycles of a fundraising campaign. Fundraising used to be more product-centric, but now a big part of the investment is vetting and building a relationship with the executive teams. Fundraising is a numbers game, and if you do get an investor on your radar screen, and the interest is really there, it is a still at most a one-in-four chance of getting through the due diligence, and an even smaller chance of being selected and funded after that. The fact is you really have to find, develop, and maintain an investor target list that includes hundreds of investors that are a fit to go after. If you understand this process, you will understand why it takes a dedicated commitment to raise capital, and therefore, why it takes so much time.

The last step, which is similarly time consuming and expensive, is to get you and your lawyer negotiating and closing the capital allocation down, and getting the cash into your account. Although there are no hard rules on this process, here are some of the things I’ve observed:

  • If you are fortunate enough to be in the right place at the right time with a compelling product or technology, you can raise your required capital in 3-6 months, but this represents a very small fraction of the players. Adding to this, angels, venture philanthropy, and patient investor groups can act swiftly, but they are a minority of investors. This is largely an issue of “passion versus risk” – meaning the venture philanthropy and patient groups move faster because of a sense of urgency in finding a cure.
  • From my firsthand accounts with fundraising clients, somewhere between 6 and 12 months is a reasonable timeline to raise capital, assuming investor climate is suitable and proper campaign execution is present.
  • The rest of the major categories of investors have firm “institutional” best practice investment processes. This means a stringent, time-consuming methodology and adhering to established protocols for the particular investment mandate. In other words, it takes time.
  • 2008 and 2011 drastically elongated fundraising timelines (for obvious reasons) to 9-18 months. This is beginning to soften now, but things can still be tough.
  • Investors are not going it alone anymore, so “herding” spells more time, as more players opt in.
  • Entrepreneurs can plan on spending around 1,000 hours (or about 9 months), which is at the top of the bell curve in my estimate. The 6-9 month point is when you will have a good idea of your funding potential in terms of investor’s feedback and interest. If it’s not working out, something needs to change.
  • A campaign is a living vehicle that needs to be honed and morphed as the investor reaction is calculated, which either enhances or delays your timeline.
  • Finding the right investor fit is critical. If you don’t achieve this, you’re looking at churn, churn and more churn – which can be expected today.

The State of Investment Banks in Early Stage Life Science Investing

17 Apr

By Max Klietmann, VP of Research, LSN

As LSN has been tracking the shift in the investor landscape over the past year or so, an interesting trend has emerged among some boutique investment banks in the space. Traditionally, investment banks in the life science arena were more focused on institutional transactions, and buy-side & sell-side activity. However, as family offices have begun to play a more significant role in the space, some tactically-minded I-banks have reoriented their businesses to focus on serving these constituents.

This is not a trend among the bulge bracket banks for several reasons: first, there is too much separation between the investment banking and private wealth business areas. This lack of communication makes it hard to consistently source direct investment opportunities for family office clients with specific interests. Secondly, family offices want industry specialists to serve as navigators in the space – they are not merely looking for an investment advisor. Finally, the family offices tend to prefer the personal touch gained by working with a smaller, more flexible boutique partner – it is simply the nature of this investor group to look for long-term relationship potential.

The boutique banks that are doing this effectively are maintaining a custom-tailored approach – they are taking a family office’s interest in a specific disease area, and enhancing their search with institutional quality deal sourcing, a high level of industry & sector expertise, and high quality due diligence processes. This yields superior results for family offices that typically have a genuine desire to make allocations, but lack the technical insight to navigate the space on their own.

So what does this mean for the space? Beyond investment banks having a new prospective client base in the life sciences space, there are some other very interesting considerations to make: Entrepreneurs targeting capital should consider boutique, industry-specific investment banks as a source of potential investors. Family offices looking to enter the space should evaluate whether one of these entities might be the right partner with which to approach direct investment in life sciences. The sands are shifting, and those that adapt to these trends first will have the upper hand.

Hot Life Science Investor Mandate 1: Venture Arm with Strong Backing Deploying Capital to Healthcare IT – April 18, 2013

17 Apr

A venture and expansion capital arm of a larger organization based in the Central US has around $300 million in total assets under management, and is currently deploying capital from its third fund, which closed at nearly $200 million. The firm is currently seeking opportunities in the life science sector, and while they have no strict timeline to make investments, they would invest in a new firm within the next 6-9 months if a compelling opportunity were identified. The firm’s equity investments range from $3-10 million, but are typically in the $8-10 million range.

Currently, this firm is most interested in the medtech, biotech diagnostics, and information providers spaces. Specifically, they are looking for healthcare IT firms within the information providers space. The firm is very opportunistic within the areas of biotech diagnostics and medtech, and would be willing to look at companies that fall within the full gamut of the medtech and diagnostics subsectors. The firm, however, will only consider US based firms within the venture and expansion capital space.

The firm is most interested in early stage companies, and is interested in pre-revenue firms. With that being said, they will look at firms that have products that are in-development, or firms that have a prototype of their product, but will not consider firms that have a device that is on the market.

Hot Life Science Investor Mandate 2: Eastern US Angel Group Targeting Orphan Indications – April 18, 2013

17 Apr

An angel group based in the Eastern US currently has around $15 million in total assets under management, and is currently deploying capital from its third fund. The firm is looking for new opportunities in the life science space, but has no set timeline to make allocations. The group typically allocates between $250,000 and $2 million per company.

Currently, the angel group is most interested in the biotech therapeutics and medtech space, but only those that are targeting orphan indications. The group will not consider therapeutics and diagnostics that are treating any other indications besides orphan diseases due to the current difficult FDA regulatory framework.

The group is looking for pre-revenue companies within this area. However, they would consider companies in the biotech therapeutics space that have products in the preclinical stage through phase III of development, and in the medtech space the firm is looking for companies that have a product in development, or have a prototype.

Hot Life Science Investor Mandate 3: Opportunistic PE Seeks CMO for New Allocations – April 18, 2013

17 Apr

A private equity group based in the Eastern US has around $200 million in assets, and has raised two funds. The firm is currently looking for new opportunities in the life sciences space, and although the firm has no set time frame to make allocations, they are always opportunistically looking to source new investments in the space.

The firm’s typical equity investment size ranges from $10-40 million. Currently, they are most interested in information providers as well as Biotech R&D services firms. In the information provider space, the group is seeking healthcare IT firms, and in the biotech R&D services space, the firm is looking for contract manufacturing organizations (CMOs). The firm solely invests in firms based in North America, and will consider companies headquartered in either the U.S. or Canada.

The firm is looking for companies that have $5-15 million in EBITDA, and $35-100 million in revenue, and $25-125 million in enterprise value, however EBITDA is the most important criteria in terms on the firms investment requirements. Accordingly, the firm does not invest in pre-revenue companies.

Hot Life Science Investor Mandate 1: Family Office Able to Deploy Capital Quickly Looking for New Opportunities – April 11, 2013

8 Apr

A single-family office based in based in the Eastern US currently manages over $1 billion in total assets, and is seeking to identify new investment opportunities in the life science space. The firm has no set time frame to make an allocation, but would invest in a firm within the next 3-6 months if a compelling opportunity were identified. Because the firm is backed by the founding family, and is not a typical fund that must go through the fundraising cycle, the firm has the ability to deploy capital as soon as an opportunity is sourced. They typically make initial investments in the $500,000 to $1 million range.

The firm is currently most interested in companies in the medical technology space. The firm has no specific areas of interest within the area of medical technology, and thus would be open to considering any kind of medical device.

The firm typically provides growth equity to firms right after they have received their Series A round. They prefer firms that have a pre-money valuation ranging from $3-5 million. The firm has a long-term investment horizon and likes to hold companies in their portfolio for much longer than a typical private equity firm.

Hot Life Science Investor Mandate 2: PE Plans to Allocate to 5-10 New Biotech, Medtech Targets in 2013 – April 11, 2013

8 Apr

A private equity group based in the Western US has around $100 million in assets, and is currently seeking new investment opportunities in the life sciences space. The firm plans to allocate to around 5-10 companies next year, and typically allocates $1-10 million per firm. The firm is most interested in medtech companies developing medical devices, as well as biotech companies that develop therapeutics.

The firm will only consider firms that currently have products on the market. The firm mainly invests in firms based in the US and Canada, but will also consider firms based in Australia. The firm prefers companies with revenue in the $5-100 million range, and whose enterprise value is less than $100 million. The firm will consider both private & small-cap, publicly owned firms. The firm provides senior secured debt financing to firms and will not take a majority stake in the company.